Insmed Reports Third Quarter 2015 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
UBS Downgrades Insmed (INSM) to Neutral; Arikayce Becomes a 2017 Story
November 9, 2015 7:59 AM ESTUBS downgraded Insmed (NASDAQ: INSM) from Buy to Neutral with a price target of $18.00 (from $35.00) based on a SOTP as Arikayce becomes a 2017 story.
Analyst Matthew Roden commented, "Insmed reported 3Q results and an incrementally negative update to the enrollment progress... More
US NTM Delayed Up to 12 Months; Cowen Cuts Price Target on Insmed (INSM) to $34
November 9, 2015 6:46 AM ESTCowen reiterated an Outperform rating on Insmed (NASDAQ: INSM), and cut the price target to $34.00 (from $38.00), folloiwng the company's 3Q15 earnings report. INSM reported Q3 EPS of ($0.50) vs consensus ($0.47). Cowen's lower price target on INSM is based on a potential 12 month delay... More
Insmed (INSM) Misses Q3 EPS by 3c
November 6, 2015 9:12 AM ESTInsmed (NASDAQ: INSM) reported Q3 EPS of ($0.50), $0.03 worse than the analyst estimate of ($0.47).
For earnings history and earnings-related data on Insmed (INSM) click here.
... More